Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Psyence Biomedical ( (PBM) ) has provided an update.
Psyence BioMed announced the effective date for its 1-for-7.97 reverse stock split, which was approved at a Special Meeting of Stockholders on April 16, 2025. The consolidation aims to help the company comply with Nasdaq’s minimum bid price requirement, with trading on a post-consolidated basis starting May 5, 2025. This move is expected to impact the company’s market operations by reducing the number of outstanding shares and potentially stabilizing its stock price.
More about Psyence Biomedical
Psyence BioMed is a biopharmaceutical company specializing in psychedelic-based therapeutics, focusing on non-synthetic psilocybin-based medicine. It is a vertically integrated company listed on Nasdaq, dedicated to addressing mental health needs, particularly in palliative care, through evidence-based psychedelic treatments.
Average Trading Volume: 34,029
Technical Sentiment Signal: Sell
Current Market Cap: $15.66M
Find detailed analytics on PBM stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue